CC-99282

Phase 2Small molecule

Bristol-Myers Squibb

CC-99282 is one of 104 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

103

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Chronic Lymphocytic Leukemia/small Lymphocytic LymphomaActive, not recruiting

Non-Hodgkin LymphomaActive, not recruiting

Follicular LymphomaActive, not recruiting

LymphomaPhase 1

Active, not recruiting

Chronic Lymphocytic Leukemia/small Lymphocytic LymphomaPhase 1

Active, not recruiting

Non-Hodgkin LymphomaPhase 2

Active, not recruiting

Follicular LymphomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

CC-99282

Bristol-Myers Squibb

Phase 2

2 2

Oncaspar

SServier

Preclinical

15 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Tafasitamab

Incyte

Preclinical

7 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Systemic Therapy

1 9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Follicular Lymphoma

NCT06108232

Q1 2028

Phase 1/2Active, not recruiting

Lymphoma

NCT03930953

Q4 2028

Phase 1Recruiting

Lymphoma

NCT04884035

Q4 2032

Phase 2Active, not recruiting

Non-Hodgkin Lymphoma

NCT05283720

Clinical

Trials by Indication[1]

Lymphoma2 trials

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03930953·438 enrolled

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04884035·174 enrolled

Follicular Lymphoma1 trial

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06108232·36 enrolled

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma1 trial

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04434196·16 enrolled

Relapsed/Refractory B-cell Malignancies1 trial

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03310619·62 enrolled

Non-Hodgkin Lymphoma1 trial

Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma

Active, not recruiting· Genmab logo

Genmab·Phase 2·NCT05283720·264 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for CC-99282. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CC-99282 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CC-99282. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

CC-99282

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Q4 2028

Q4 2032

Trials by Indication[1]

Lymphoma2 trials

Follicular Lymphoma1 trial

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma1 trial

Relapsed/Refractory B-cell Malignancies1 trial

Non-Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News